Relay Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue: | ||
| License and other revenue | $3,000 | $7,679 |
| Total revenue | 3,000 | 7,679 |
| Operating expenses: | ||
| Research and development expenses | $70,563 | $73,809 |
| General and administrative expenses | 11,027 | 18,739 |
| Total operating expenses | 81,590 | 92,548 |
| Loss from operations | (78,590) | (84,869) |
| Other income: | ||
| Interest income | 5,352 | 7,813 |
| Other expense | (53) | (9) |
| Total other income, net | 5,299 | 7,804 |
| Net loss | $(73,291) | $(77,065) |
| Net loss per share, basic and diluted | $(0.41) | $(0.46) |
| Weighted average shares of common stock, basic and diluted | 179,849,137 | 169,233,155 |
| Other comprehensive (loss) income: | ||
| Unrealized holding (loss) gain | (172) | 1,029 |
| Total other comprehensive (loss) income | (172) | 1,029 |
| Total comprehensive loss | $(73,463) | $(76,036) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.